Desmoines News Desk

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market is Expected to Grow at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight

 Breaking News
  • No posts were found

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market is Expected to Grow at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight

May 25
15:22 2023
Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market is Expected to Grow at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight
Delveinsight Business Research LLP
The Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) size in the 7MM was approximately USD 982 million in 2021, which is expected to increase by 2032 at a decent CAGR. As per DelveInsight, the Pulmonary Hypertension Associated with Interstitial Lung Disease Market is anticipated to evolve immensely in the coming years owing to the expected launch of potential therapy assisted by an increase in the diagnosed prevalent population of PH-ILD in the 7MM.

DelveInsight’s “Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pulmonary Hypertension Associated with Interstitial Lung Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Pulmonary Hypertension Associated with Interstitial Lung Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD): An Overview

Pulmonary hypertension, or PH, occurs when blood pressure within the lungs becomes abnormally elevated. It can be caused by a thickening of the pulmonary artery walls, heart failure, lung disease (such as interstitial lung disease), and clots within the lungs’ blood vessels. It is an important complication of several interstitial lung diseases (ILDs) and can adversely affect patient outcomes.

Development of PH-ILD is associated with an increased need for supplemental oxygen, reduced mobility, and decreased survival. Symptoms of PH are similar to those of ILD. Patients with PH often complain of shortness of breath with physical activity that gradually worsens over time. Patients may also experience chest pain, fainting episodes, and difficulty breathing when lying flat, and swelling of the ankles. In ILD patients, pulmonary hypertension is usually suspected when these symptoms are out of proportion to the severity of the patient’s ILD.

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market Key Facts

  • Among all the 7MM, the US consistently captured the highest market with approximately USD 676 million in 2021, which is expected to grow during the forecasted period (2022-2032).

  • In 2021, EU4 and the UK countries captured an estimated USD 211 million, which is expected to rise by 2032.

  • Upcoming therapy such as Tyvaso (in Europe and Japan), INOpulse, and others have the potential to create a significant positive shift in the Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) market size.

  • In 2021, the total diagnosed prevalent cases of ILD were 894,597 and PH-ILD were 166,375 cases in the 7MM, which is expected to rise by 2032.

  • Among 7MM, the United States had the highest diagnosed prevalent cases of PH-ILD with 87,295 cases in 2021.

  • EU4 and the UK countries accounted for 57,138 diagnosed prevalent cases of PH-ILD in 2021 and are projected to increase by 2032. In 2021, with 13,868 cases, Germany accounted for the highest number of diagnosed prevalent cases of PH-ILD, followed by the UK (13,166 cases). On the other hand, Spain had the lowest and equal number of diagnosed prevalent populations with approximately 8,954 cases in 2021.

Pulmonary Hypertension Associated with Interstitial Lung Disease Market

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Pulmonary Hypertension Associated with Interstitial Lung Disease market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Pulmonary Hypertension Associated with Interstitial Lung Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology, Segmented as –

  • Total Prevalence of Interstitial Lung Diseases (ILD) in the 7MM [2019-2032]

  • Type-specific cases (sarcoidosis, connective tissue diseases, idiopathic pulmonary fibrosis) of PH-ILD in the 7MM [2019-2032]

  • Type-specific cases (sarcoidosis, connective tissue diseases, idiopathic pulmonary fibrosis) of ILD in the 7MM [2019-2032]

  • Diagnosed and Treatable cases of PH-ILD in the 7MM [2019-2032]

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Pulmonary Hypertension Associated with Interstitial Lung Disease market or expected to be launched during the study period. The analysis covers the Pulmonary Hypertension Associated with Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pulmonary Hypertension Associated with Interstitial Lung Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Pulmonary Hypertension Associated with Interstitial Lung Disease Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Therapeutics Analysis

The pipeline of Pulmonary Hypertension Associated With Interstitial Lung Disease is not so robust. There are not many innovative key players involved in the development of promising products. However, the Pulmonary Hypertension Associated with Interstitial Lung Disease Therapeutics market will evolve immensely in the coming years owing to the extensive research and development activities of pharmaceutical companies, along with the launch of various multiple-stage pipeline products in the market. 

Leading Players in the Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Therapeutics Market Include

  • Insmed Incorporated

  • Bellerophon Therapeutics

And Many Others

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Emerging and Marketed Drugs Covered in the Report Include:

  • TYVASO/TYVASO DPI (treprostinil): United Therapeutics Corp.

  • Treprostinil Palmitil: Insmed Incorporated

  • INOpulse: Bellerophon Therapeutics

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Pulmonary Hypertension Associated with Interstitial Lung Disease Competitive Intelligence Analysis

4. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Overview at a Glance

5. Pulmonary Hypertension Associated with Interstitial Lung Disease Disease Background and Overview

6. Pulmonary Hypertension Associated with Interstitial Lung Disease Patient Journey

7. Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Pulmonary Hypertension Associated with Interstitial Lung Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Pulmonary Hypertension Associated with Interstitial Lung Disease Unmet Needs

10. Key Endpoints of Pulmonary Hypertension Associated with Interstitial Lung Disease Treatment

11. Pulmonary Hypertension Associated with Interstitial Lung Disease Marketed Products

12. Pulmonary Hypertension Associated with Interstitial Lung Disease Emerging Drugs and Latest Therapeutic Advances

13. Pulmonary Hypertension Associated with Interstitial Lung Disease Seven Major Market Analysis

14. Attribute Analysis

15. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Outlook (In US, EU5, and Japan)

16. Pulmonary Hypertension Associated with Interstitial Lung Disease Access and Reimbursement Overview

17. KOL Views on the Pulmonary Hypertension Associated with Interstitial Lung Disease Market

18. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Drivers

19. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight

India Healthcare Outlook Report

“India Healthcare Outlook Report, 2023,” provides comprehensive insights into the healthcare scenario, regulatory policies, and reimbursement landscape in India. The report also identifies key trends in the healthcare market and provides insights into the demographic and healthcare infrastructure of the country. Along with this, the report also provides a brief look into the trends and segmentation of the Indian pharmaceutical and medical devices market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories